Global biotherapeutics leader CSL Behring will host a patient-focused symposium about Alpha-1 Antitrypsin Deficiency (AATD) on Monday, 30 September, during the 29th International Congress of the European Respiratory Society (ERS) in Madrid.  ERS is the largest meeting of respiratory professionals in the world and features a scientific and educational programme designed to address […]

Global biotherapeutics leader CSL Behring announced that the US Food and Drug Administration (FDA) has approved 4- and 5-gram vial sizes for ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)], its therapy for treating Alpha 1 Antitrypsin Deficiency (Alpha 1).  This approval is significant for the Alpha 1 community as ZEMAIRA was previously available only in […]